BioCentury | Apr 30, 2019
Distillery Therapeutics

The Parkinson's drug Comtam for obesity and diabetes

...DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; diabetes In silico and mouse studies identified Comtan entacapone as an...
...testing Comtan in additional models of obesity and diabetes. Novartis AG and Orion Corp. market Comtan...
...University, Beijing, China email: zhangerquan@nibs.ac.cn CONTACT: Niu Huang, same affiliation as above email: huangniu@nibs.ac.cn Sandi Wong Comtan, entacapone Chinese...
BioCentury | Nov 2, 2016
Distillery Therapeutics

Neurology

...Tasmar tolcapone to treat PD. Novartis AG and Orion Corp. market the COMT inhibitor Comtan entacapone...
BioCentury | May 19, 2016
Distillery Therapeutics

Therapeutics: Catechol-O-methyl-transferase (COMT)

...activity of human COMT with greater potency than the COMT inhibitors Tasmar tolcapone and Comtan entacapone...
...cell line, the compound induced less mitochondrial toxicity than Tasmar and induced toxicity comparable to Comtan...
...in PD models. Roche markets Tasmar to treat PD. Novartis AG and Orion Corp. market Comtan...
BioCentury | Nov 9, 2015
Clinical News

LECIGon: Phase I data

...Sweden Product: LECIGon Business: Neurology Molecular target: NA Description: Gel formulation of levodopa, carbidopa and entacapone...
BioCentury | Mar 30, 2015
Clinical News

Opicapone: Phase III data

...levodopa (2 vs. 0.9 hours, p=0.0005). Opicapone plus levodopa was non-inferior to the active comparator entacapone...
...investigators’ and subjects’ global assessment of change vs. both placebo (p=0.0005 and p=0.0008, respectively) and entacapone...
...p=0.007 and p=0.0091, respectively) plus levodopa. Opicapone was well tolerated. Patients received placebo, 200 mg entacapone...
BioCentury | Jan 5, 2015
Clinical News

ND0612H: Phase IIa data

...plasma levodopa concentrations of 1,333 and 1,436 ng/mL. ND0612H given with adjunct dosing of oral entacapone...
...carbidopa led to maximum daytime plasma levodopa concentrations of 528 and 477 ng/mL. ND0612L plus entacapone...
BioCentury | Jan 5, 2015
Clinical News

ND0612L: Phase IIa data

...plasma levodopa concentrations of 1,333 and 1,436 ng/mL. ND0612H given with adjunct dosing of oral entacapone...
...carbidopa led to maximum daytime plasma levodopa concentrations of 528 and 477 ng/mL. ND0612L plus entacapone...
BioCentury | Dec 31, 2014
Top Story

NeuroDerm nearly triples on Phase II PD data

...plasma levodopa concentrations of 1,333 ng/mL and 1,436 ng/mL, while a dose given with oral entacapone...
...levels led to maximum daytime concentrations of 528 ng/mL and 477ng/mL, while a combination with entacapone...
BioCentury | Nov 10, 2014
Clinical News

ND0612L: Phase II data

...30 patients were offered an additional week of treatment with ND0612L with or without oral entacapone...
BioCentury | Nov 10, 2014
Clinical News

ND0612H: Preliminary Phase IIa data

...patients with advanced PD showed that subcutaneous ND0612H given alone and in combination with oral entacapone...
Items per page:
1 - 10 of 57